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A B S T R A C T
Background
Napkin dermatitis (nappy or diaper rash) is a non-specific term used to describe inflammatory eruptions (rashes) in the napkin area.
Most infants develop napkin dermatitis at least once during their infancy. Topical vitamin A has been suggested as a treatment for
napkin dermatitis.
Objectives
To determine if treatment with topical vitamin A is successful in either preventing napkin dermatitis, or producing resolution or
decreasing the severity of napkin dermatitis.
Search strategy
We searched the Cochrane Skin Group Specialised Register (May 2005); Cochrane Central Register of Controlled Trials (CENTRAL)
(The Cochrane Library Issue 3, 2005); Ovid MEDLINE from 1966 to August 2005; EMBASE (2003 to May 2005); Ovid OLDMED-
LINE (1950 to 1965); and CINAHL (1982 to August 2005). We also searched reference lists of articles.
Selection criteria
Randomised controlled trials, where the topical application of medication containing vitamin A (or its derivatives) was compared with
either placebo, no treatment or other topical medication, for the prevention or treatment of napkin dermatitis in infants aged from
zero to two years.
Data collection and analysis
Two authors (AJD and MWD) identified and checked titles and abstracts obtained from the searches, and reviewed the full text where
necessary. They decided which trials met the inclusion criteria, and recorded their methodological quality. They assessed studies as
either adequate, unclear or inadequate using the following key criteria: (a) randomisation (method of generation and concealment of
allocation); (b) blinding; (c) loss to follow-up.
Main results
We did not find any studies for the treatment of napkin dermatitis. We found only one study comparing the use of topical application
of medication containing vitamin A, with another topical medication or placebo, to prevent napkin dermatitis. This included study, of
114 newborn infants, reported no significant differences between groups with regard to the severity or duration of napkin dermatitis.
Authors’ conclusions
For the treatment of napkin dermatitis there is no evidence to support or refute the use of topical vitamin A preparations. For the
prevention of napkin dermatitis there is no evidence to suggest that topical vitamin A alters the development of napkin dermatitis.
Further RCTs are required to determine whether topical vitamin A is efficacious in treating or preventing napkin dermatitis.
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P L A I N L A N G U A G E S U M M A R Y
There is not enough evidence to support the use of vitamin A to treat nappy rash.
Nappy or diaper rash is a term used to describe inflammation in babies’ napkin area. Whilst nappy rash does not make babies very sick,
it is very common and it causes varying levels of discomfort to infants and concern to parents. Ointments that contain vitamin A have
been suggested as possible treatments for napkin rash. Our review found that there is not enough evidence to say whether vitamin A
is effective for treating or preventing napkin rash; more research is needed. One small trial found that applying vitamin A in the first
three months of life did not prevent napkin rash.
B A C K G R O U N D
Definition
Napkin dermatitis (also known as nappy rash or diaper rash) is
a non-specific term used to describe inflammatory eruptions in
the napkin area. Nappy rash is most commonly characterised by
confluent erythema (i.e. joined patches of redness) of the convex
surfaces of the buttocks, the areas of skin in closest contact with
the nappy (Atherton 1998).
Impact
Most infants develop such an eruption at least once during their
infancy, and napkin dermatitis is the most common cause for der-
matological consultation in infancy (Concannon 2001). Napkin
dermatitis is most commonly seen between six and 12 months of
age (Lane 1990).
Causes
The exact cause of napkin dermatitis remains unclear (Atherton
1998). Friction and maceration (i.e. the softening of skin by soak-
ing) are recognised as key causative factors in the pathogenesis of
napkin dermatitis (Atherton 1998). Increased hydration increases
the risk of frictional damage and impairs the skin’s barrier func-
tion, increasing its susceptibility to irritants. Increased skin wet-
ness allows growth of micro-organisms on the surface of the skin
(Lane 1990). Friction may produce the initial breach in the pro-
tective coating of the skin. The preterm infant is more vulnerable
to mechanical injury because of its thin stratum corneum, lack of
dermal papillary projections and a thinner, less collagenised der-
mis (Williams 2001). Contact with components of urine and fae-
ces and the contribution of micro-organisms in the napkin area
have also been considered as possible causative agents in napkin
dermatitis (Atherton 1998). Faeces contain a variety of bacteria,
some of which contain urease, which releases ammonia from the
urine and raises the pH (Lane 1990). Ammonia is considered a
contributory cause in the aetiology of napkin dermatitis as it is
only irritant when applied to a damaged stratum corneum (Lane
1990). Faeces contain other enzymes such as proteases and lipases
which also irritate the skin of infants (Lane 1990). Faecal enzymes
also increase the permeability of the skin to bile salts, which act as
irritants to the skin (Wong 1992). Occlusion of the skin, by means
such as napkins, elevates the surface pH (Lane 1990). Increased
urinary pH is a contributory factor in napkin dermatitis through
its action in increasing the activity of irritant faecal enzymes (Fis-
cher 2002).
Treatment
Numerous treatments have been tried for napkin dermatitis, with
varying success. Current treatment regimens emphasise the type
of nappies used and the skin care of the napkin region (Atherton
1998). It is suggested that good quality disposable napkins and
frequent nappy changes may decrease the incidence of maceration
and thus the incidence of nappy rash (Atherton 1998). Specific
therapies aimed at reducing the inflammation of the napkin area
may also be employed. Traditional topical napkin rash treatments
included topical corticosteroids used in isolation and combina-
tion preparations of anticandidal and antibacterial agents with cor-
ticosteroids. Topical vitamin A has been suggested as a possible
treatment for napkin dermatitis and is contained in many prepa-
rations available for the treatment of napkin dermatitis. Vitamin
A deficiency can cause skin changes and subclinical deficiency of
vitamin A has been associated with increased infections (including
skin) (Soni 1999).
Adverse effects
Consideration must be given to potential side effects as a re-
sult of systemic absorption of topical preparations in infants and
neonates. The keratinised stratum corneum is the skin’s major pro-
tection against absorption (Evans 1986). Keratinisation begins at
22 weeks gestation (Haake 1999) and infant skin demonstrates
barrier function similar to that of an adult by 32 weeks gestation
(Rutter 1988). Barrier function of the stratum corneum develops
rapidly after birth (regardless of gestation), achieving the epider-
mal development of the term infant at two weeks of age (Rutter
1988). The penetration of the skin is altered by site, reflecting the
varying thickness of the stratum corneum (Shupack 1999).
The absorption of retinoic acid (an oxidized metabolite of vita-
min A) through the skin is limited (approximately 2%), and is
not increased despite long term administration (Latriano 1997;
Shapiro 1998). Differing formulations of retinoic acid did not al-
ter percutaneous absorption (Latriano 1997). No rise in retinoic
acid levels has been demonstrated regardless of the surface area
of application (Latriano 1997). Minimal percutaneous absorption
of retinoic acid suggests that the adverse effects of oral retinoid
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therapy (e.g. teratogenicity, mucocutaneous and gastrointestinal
disturbances) are unlikely with topical applications. Topical ap-
plication of retinoic acid has been associated with some local ad-
verse effects (predominantly in adults for the treatment of acne).
Common adverse effects of topical retinoic acid include increased
solar sensitivity and local irritation, causing erythema and peeling
(Skov 1997).
O B J E C T I V E S
The primary objectives were to determine if treatment with topi-
cal vitamin A is successful in either preventing napkin dermatitis,
or producing resolution or decreasing the severity of napkin der-
matitis.
A secondary objective was to establish if topical application of
vitamin A in infants is associated with adverse outcome.
The protocol for this review was for treatment of napkin dermati-
tis with Vitamin A . Since the only study found dealt with preven-
tion we decided (after discussion with the editors) to change the
title and objectives of this review to include both treatment and
prevention . All searches were re-run to reflect the new objectives.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
Randomised controlled trials including cross-over studies. For
cross-over studies, we would only have used data regarding out-
comes assessed at the end of the first randomisation period (before
the first cross-over). We intended to exclude quasi-randomised tri-
als.
Types of participants
Infants aged from zero to two years.
Types of intervention
Topical application of medication containing vitamin A (or its
derivatives) compared with placebo or no treatment or other top-
ical medication.
Types of outcome measures
(1) Primary outcome measures
(a) Number of infants with any rash at seven days, two, four or
eight weeks;
(b) Number of infants with complete resolution of rash at seven
days, two, four or eight weeks;
(c) Number of infants with a decrease in the severity of the rash.
The severity of the eruption being assessed by the following scale:
• severe: skin breakdown;
• mild/moderate: presence of any rash;
• absent: nil rash.
(2) Secondary outcome measures
(a) Number of infants with increased severity of rash.
(b) Duration of napkin dermatitis (days).
(c) Serum vitamin A level at seven days, two, four and eight weeks.
(d) Number of infants with clinical signs of vitamin A toxicity (e.g.
poor feeding, poor weight gain, generalised pruritus, dry cracked
skin (not of napkin area), hepatomegaly i.e. enlarged liver).
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Skin Group methods used in reviews.
(1) Electronic databases
(a) We searched The Cochrane Skin Group Specialised Register
(May 2005) using the following terms:
(napp* or napkin* or diaper* or infant* or bab*) and (rash* or
dermatitis or erythema*) AND (retinoid* or acetretin or etretinate
or fenretinide or isotretinoin or retinaldehye or (vitamin and A)
or tretinoin).
(b) We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) The Cochrane Library Issue 3, 2005 using the
search strategy displayed in Table 01.
(c) We searched Ovid MEDLINE(R) from 1966 to 18th August
2005 using the following search strategy:
1. (infant or baby).mp. [mp=title, original title, abstract, name of
substance word, subject heading word]
2. (’DIAPER RASH’ or ’ napkin rash’ or ’napkin dermatitis’ or
’diaper dermatitis’ or ’nappy rash’).mp. [mp=title, original title,
abstract, name of substance word, subject heading word]
3. (’RETINOIDS’ or ’Acetretin’ or ’ Etretinate’ or ’Fenretinide’
or ’Isotretinoin’ or ’Retinaldehyde’ or ’Vitamin A’).mp. [mp=title,
original title, abstract, name of substance word, subject heading
word]
4. 1 and 2 and 3
(d) We searched EMBASE from 2003 to May 2005 using the
search strategy displayed in Table 02.
(e) We searched OLDMEDLINE (Ovid) from 1950 to 1965 using
the search strategy displayed in Table 03.
(f ) We searched CINAHL (Cumulative Index to Nursing & Allied
Health Literature) 1982 to August Week 2 2005 using the search
strategy displayed in Table 04.
(2) References from published studies
We checked references from published studies for further trials.
(3) Unpublished literature
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We attempted to identify unpublished trials, ongoing trials, and
grey literature using reference lists of studies, reviews and book
chapters.
(4) Language
We did not impose any language restrictions.
M E T H O D S O F T H E R E V I E W
(1) Study selection
Two authors (AJD and MWD) identified and checked the titles
and abstracts obtained from the searches. The same two authors
obtained the full text of all studies of possible relevance for in-
dependent assessment. Two authors (AJD and MWD) decided
which trials met the inclusion criteria, and recorded their method-
ological quality. Any disagreement was resolved by discussion be-
tween the authors.
(2) Assessment of methodological quality
We assessed studies using the following key criteria:
(a) randomisation (method of generation and concealment of al-
location)
(b) blinding (blinding of observers / participants to the treatment
allocation)
(c) loss to follow-up (presence of dropouts and withdrawals, and
the analysis of these).
We categorised each component as adequate, unclear or inade-
quate.
Randomisation (allocation generation): adequate when the alloca-
tion sequence protects against biased allocation to the comparison
groups
Randomisation (allocation concealment): adequate when the clin-
icians and participants are unaware of future allocations
Blinding: adequate when the outcome assessor is unaware of the
allocation
Loss to follow-up: adequate when more than 80% of participants
are followed up, and analysed in the groups to which they were
originally randomised (intention to treat).
(3) Data extraction
Two authors (AJD and MWD) independently extracted the data.
Differences would have been resolved by discussion and consensus
between the authors.
(4) Analysis
If sufficient studies had been identified and included in this re-
view we would have performed a sensitivity analysis based on the
methodological quality of the studies.
For individual trials, where possible, mean differences (and 95%
confidence intervals) are reported for continuous variables such
as duration of rash. For categorical outcomes such as ’resolution
of rash’, the relative risk and risk difference (and 95% confidence
intervals) are reported.
For the meta-analysis, where possible, we would have reported
weighted mean differences (and 95% confidence intervals) for
continuous variables, and the pooled relative risk and risk differ-
ence (and 95% confidence intervals) for categorical outcomes. We
would have used a random effects model.
For cross-over studies we would only have used data regarding
outcomes assessed at the end of the first randomisation period
(before the first cross-over).
Subgroup analyses were planned to determine whether results dif-








3. Adjunct therapy used
(a) other topical preparations used;
(b) types of napkins used (reusable versus disposable and type of
disposable used).
D E S C R I P T I O N O F S T U D I E S
Using the above search process we found only one study (Bosch-
Banyeras 1988).
For treatment of napkin dermatitis:
• no studies were found comparing the use of topical application
of medication containing vitamin A with placebo, no treatment
or other topical medication.
For prevention of napkin dermatitis:
• no studies were found comparing the use of topical application
of medication containing vitamin A with placebo or no treat-
ment;
• one study (Bosch-Banyeras 1988) was found comparing the use
of topical application of medication containing vitamin A with
another topical medication.
114 newborn infants were allocated to the use one of two creams.
The control group (N = 56) received topical application of a cream
with the following ingredients: Lassar’s plain zinc paste 30 grams,
lanolin 20 grams, petrolatum 10 grams. The study group (N =
58) received topical application of a cream with the following
ingredients: Lassar’s plain zinc paste 30 grams, lanolin 20 grams,
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petrolatum 10 grams, vitamin A ester palminate 1000 IU/gram.
The two creams were indistinguishable (Bosch-Banyeras 1988).
Upon discharge from hospital after the birth of their child, moth-
ers were advised to apply the cream when changing diapers and to
clean the diaper area with a moist sea-sponge. Infants were exam-
ined every 15 days for six follow up visits. At each visit they were
assessed for the presence or absence of diaper rash. Diaper rash
severity was graded as follows: 0 = absence of diaper rash; 1 = min-
imal, no contiguous spotty erythema and no swelling; 2 = slight,
rather contiguous erythema and slight evidence of swelling; 3 =
moderate continuous erythema and swelling, and lesions present;
4 = severe erythema and swelling with multiple lesions and exco-
riated areas.
Infants were excluded from the study if other topical or systemic
medication were prescribed for the rash. The control and treat-
ment groups were similar in terms of frequency of diaper change
and bowel motions. There was also no reported difference in the
percentage of breastfed infants in either intervention group. One
infant in the study group was excluded because the paediatrician
had prescribed topical and systemic medication for napkin rash.
M E T H O D O L O G I C A L Q U A L I T Y
In the Bosch-Banyeras 1988 study:
• randomisation (allocation generation) was unclear - group al-
location was randomised but the method of randomisation was
not described;
• randomisation (allocation concealment) was adequate - sealed
opaque envelopes were used;
• blinding was adequate - treatment was blinded for both ob-
servers and participant’s caregivers;
• loss to follow-up was adequate - all infants were accounted for
at the end of the study.
R E S U L T S
Treatment of napkin dermatitis
We did not find any studies comparing the use of topical applica-
tion of medication containing vitamin A with placebo, no treat-
ment or other topical medication.
Prevention of napkin dermatitis
We did not find any studies comparing the use of topical applica-
tion of medication containing vitamin A with no treatment.
We found one study (Bosch-Banyeras 1988) comparing the use
of topical application of medication containing vitamin A with
another topical medication.
The single included study (Bosch-Banyeras 1988) of the use of Vi-
tamin A containing cream for the prevention of napkin dermatitis
reported that there were no significant differences between groups
with regard to the severity or duration of napkin dermatitis. The
trial authors reported the frequency distribution for mean rash
scores over all six follow-up visits and the frequency distribution
of the number of visits at which they had any rash. See Additional
Table 01 and Table 02 for reproductions of the tables from Bosch-
Banyeras 1988. Our specific outcome ’the number of infants with
any rash’ was not reported. None of the following relevant out-
comes were included in this study: number of infants with any
rash; duration of napkin dermatitis; serum vitamin A levels; num-
ber of infants with clinical signs of vitamin A toxicity. Therefore,
there are no quantitative data available on any outcomes that we
considered relevant.
D I S C U S S I O N
There is no information available from RCTs on the efficacy of
vitamin A for the treatment of napkin dermatitis.
There is one small, poorly reported, RCT on the use of vitamin
A containing cream for preventing napkin dermatitis. This study
was randomised and its major strength is that the two creams used
in the study (one with and one without vitamin A) were indistin-
guishable, allowing adequate blinding of the treatment for both
caregivers and investigators. The group allocation was adequately
concealed. 114 infants were studied and they were only followed
up for three months: napkin dermatitis is most commonly seen
between six and 12 months of age. Nevertheless, the trial authors
report that the incidence and severity of napkin dermatitis did not
differ between groups. Given the population studied there is no
information on differences with regard to the gestational age of
the infant. There was also no assessment of systemic side effects
or the relative efficacy of ointments versus creams.
We can only speculate on the reasons for the dearth of studies using
topical vitamin A to prevent or treat napkin dermatitis. It may
well be because of the perceived lack of adverse effects of topical
vitamin A. This of course ignores the cost of such treatments and
the false reassurance given to parents of affected infants.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• There is no evidence to support or refute the use of vitamin A
for the prevention or treatment of napkin dermatitis.
• The review found only one single, small, poorly-reported RCT
of topical vitamin A which showed no alteration in the devel-
opment of napkin dermatitis in the first three months of life.
• For treatment of napkin dermatitis: there is no evidence to
support or refute the use of vitamin A for the treatment of
napkin dermatitis.
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• For prevention of napkin dermatitis: there is no evidence to
suggest that topical vitamin A alters the development of napkin
dermatitis given that there is only one single, small, poorly-re-
ported RCT of topical vitamin A which showed no alteration in
the development of napkin dermatitis in the first three months
of life. Given the available data, the usage of preparations con-
taining vitamin A for the prevention of napkin dermatitis can-
not be recommended.
Implications for research
Further RCTs are required to determine whether topical vitamin
A is efficacious in preventing or treating napkin dermatitis. These
studies should also determine if there is any systemic toxicity as-
sociated with topical vitamin A application in infants. The rela-
tive efficacy of vitamin A derivatives in cream and ointment base
should also be considered.
P O T E N T I A L C O N F L I C T O F
I N T E R E S T
None known.
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T A B L E S
Characteristics of included studies
Study Bosch-Banyeras 1988
Methods Design - randomised controlled trial.
Method of allocation concealment - sealed opaque envelopes.
Method of generating randomisation sequence - unknown.
Blinding: participant - yes.
Blinding: clinician - yes.
Blinding: outcome assessment - yes.
Participants 114 newborn infants.
Inclusion criteria: healthy newborn infants.
Exclusion criteria: a history of atopic dermatitis, urticaria, allergic disorders, skin sensitivity, or a brother
with severe diaper rash; infants receiving systemic or topical medication; being breast fed by mothers taking
medication excreted in breast milk.
Setting: not specifically stated.
Gender: male or female.
Duration: Each participant returned once every 15 days for 6 follow-up visits.
Interventions Each infant was allocated to use one of two creams (below) applied to the napkin area at the time of each
diaper change.
Control group - topical application of a cream with the following ingredients: Lassar’s plain zinc paste 30
grams, lanolin 20 grams, petrolatum 10 grams.
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Characteristics of included studies (Continued )
Study group - topical application of a cream with the following ingredients: Lassar’s plain zinc paste 30 grams,
lanolin 20 grams, petrolatum 10 grams, vitamin A ester palminate 1000 IU/gram.
Outcomes Each participant returned once every 15 days for 6 follow-up visits. At each visit they were assessed for the
presence or absence of diaper rash.
Diaper rash severity was graded as follows:
0 = absence of diaper rash;
1 = minimal, no contiguous spotty erythema and no swelling;
2 = slight, rather contiguous erythema and slight evidence of swelling;
3 = moderate continuous erythema and swelling, and lesions present;
4 = severe erythema and swelling with multiple lesions and excoriated areas.
A ’mean’ score was then calculated for each infant over the six visits.
Notes
Allocation concealment A
IU - international units.
A D D I T I O N A L T A B L E S
Table 01. Search strategy for CENTRAL
Search strategy
Ovid EBM Reviews - Cochrane Central Register of Controlled Trials 3rd Quarter 2005
1. (infant or baby).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
2. (’DIAPER RASH’ or ’ napkin rash’ or ’napkin dermatitis’ or ’diaper dermatitis’ or ’nappy rash’).mp. [mp=title, original title,
abstract, mesh headings, heading words, keyword]
3. (’RETINOIDS’ or ’Acetretin’ or ’ Etretinate’ or ’Fenretinide’ or ’Isotretinoin’ or ’Retinaldehyde’ or ’Vitamin A’).mp. [mp=title,
original title, abstract, mesh headings, heading words, keyword]
4. 1 and 2 and 3
Ovid EBM Reviews - Cochrane Central Register of Controlled Trials 3rd Quarter 2005
1. (infant or baby).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
2. (’DIAPER RASH’ or ’ napkin rash’ or ’napkin dermatitis’ or ’diaper dermatitis’ or ’nappy rash’).mp. [mp=title, original title,
abstract, mesh headings, heading words, keyword]
3. (’RETINOIDS’ or ’Acetretin’ or ’ Etretinate’ or ’Fenretinide’ or ’Isotretinoin’ or ’Retinaldehyde’ or ’Vitamin A’).mp. [mp=title,
original title, abstract, mesh headings, heading words, keyword]
4. 1 and 2 and 3
Table 02. Search strategy for EMBASE
Search strategy




4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
7. assign$.mp.
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Table 02. Search strategy for EMBASE (Continued )
Search strategy
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. (infant or baby).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
15. exp DERMATITIS/ or dermatitis.mp.
16. 14 and 15
17. exp Diaper Dermatitis/ or nappy rash.mp.
18. erythema.mp. or exp ERYTHEMA/
19. 14 and 18
20. 16 or 17 or 19
21. vitamin A.mp. or exp Retinol/
22. retinoid$.mp. or exp RETINOID/
23. exp acetretin/ or exp Retinoid Derivative/ or acetretin.mp. or exp Etretinate/
24. (fenretinide or isotretinoin or retinaldehyde or tretinoin).mp. [mp=title, abstract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug manufacturer name]
25. 21 or 22 or 23 or 24
26. 13 and 20 and 25
27. limit 26 to yr=2003 - 2005
Table 03. Search strategy for OLDMEDLINE
Search strategy
Ovid OLDMEDLINE(R) 1950 to 1965
1. (infant or baby).mp. [mp=title, keyword heading, keyword heading word]
2. (’DIAPER RASH’ or ’ napkin rash’ or ’napkin dermatitis’ or ’diaper dermatitis’ or ’nappy rash’).mp. [mp=title, keyword heading,
keyword heading word]
3. (’RETINOIDS’ or ’Acetretin’ or ’ Etretinate’ or ’Fenretinide’ or ’Isotretinoin’ or ’Retinaldehyde’ or ’Vitamin A’).mp. [mp=title,
keyword heading, keyword heading word]
4. 1 and 2 and 3
Table 04. Search strategy for CINAHL
Search strategy
CINAHL - Cumulative Index to Nursing & Allied Health Literature 1982 to August Week 2 2005
1. (infant or baby).mp. [mp=title, subject heading word, abstract, instrumentation]
2. (’DIAPER RASH’ or ’ napkin rash’ or ’napkin dermatitis’ or ’diaper dermatitis’ or ’nappy rash’).mp. [mp=title, subject heading
word, abstract, instrumentation]
3. (’RETINOIDS’ or ’Acetretin’ or ’ Etretinate’ or ’Fenretinide’ or ’Isotretinoin’ or ’Retinaldehyde’ or ’Vitamin A’).mp. [mp=title,
subject heading word, abstract, instrumentation]
4. 1 and 2 and 3
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Table 05. from Bosch-Banyeras 1998, Table 1
Mean severity Group A [vit. A] Group B [control]
Table 1. Severity of symptoms observed during the six follow-up visits
Mean severity Group A [vit. A] Group B [control]














Mann-Whitney U test = 1423, standardized U = 1.14<1.96.
Table 06. from Bosch-Banyeras 1998, Table 2
Follow-up visit No. Group A [vit. A] Group B [control] Total
Table 2. Distribution of infants according to the number of follow-up visits in which symptoms were present.
Follow-up visit No. Group A [vit. A] Group B [control] Total
N = 58 N = 56
0 29 34 63
1 13 11 24
2 8 5 13
3 4 3 7
4 0 2 2
5 3 0 3
6 1 1 2
Mean (2 weeks) 1.06 0.78 -
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Table 06. from Bosch-Banyeras 1998, Table 2 (Continued )
Follow-up visit No. Group A [vit. A] Group B [control] Total
SD (2 weeks) 1.48 1.28 -
Chi-square test = 1.505; df = 3; p > 0.5.
G R A P H S A N D O T H E R T A B L E S
This review has no analyses.
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